LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

@article{Seymour2019LACEBioVO,
  title={LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.},
  author={Leonard W. Seymour and Gw{\'e}na{\"e}l Le Teuff and Elisabeth Brambilla and Frances A. Shepherd and Julio Soria and Robert Kratzke and Stephen Graziano and J Y Douillard and Rafael Rosell and Anthony Reiman and Benjamin Lacas and Béranger Lueza and Sarit Aviel-Ronen and A. Mcleer and Thierry Le Chevalier and Reinhard Pirker and Martin Filipits and Ariane Dunant and Jean Pierre Pignon and Makepeace Tsao},
  journal={Clinical lung cancer},
  year={2019},
  volume={20 2},
  pages={
          66-73.e6
        }
}
BACKGROUND Complete resection of non-small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. MATERIALS AND METHODS The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Non-functional isoforms confound the use of ERCC1 as a biomarker in nonesmall-cell lung cancer

L Friboulet, KA Olaussen, JP Pignon
  • N Engl J Med
  • 2013
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
VIEW 1 EXCERPT

SCAT phase III trial: adjuvant CT based on BRCA1 levels in NSCLC Nþ resected patients. Final survival results: a Spanish Lung Cancer Group trial

B Massuti, MC Dols, M Rodriguez-Paniagua
  • Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer;
  • 2017
VIEW 1 EXCERPT

Prognostic and predictive effect of TP53 mutations in non-small cell lung

X Ma, G Le Teuff, B Lacas
  • J Thorac Oncol
  • 2016

Prognostic effect of tumor lymphocytic infiltration in resectable nonesmall-cell lung cancer

E Brambilla, G Le Teuff, S Marguet
  • J Clin Oncol
  • 2016